RT Journal Article
T1 Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.
A1 Cavagna, Lorenzo
A1 Trallero-Araguás, Ernesto
A1 Meloni, Federica
A1 Cavazzana, Ilaria
A1 Rojas-Serrano, Jorge
A1 Feist, Eugen
A1 Zanframundo, Giovanni
A1 Morandi, Valentina
A1 Meyer, Alain
A1 Pereira da Silva, Jose Antonio
A1 Matos Costa, Carlo Jorge
A1 Molberg, Oyvind
A1 Andersson, Helena
A1 Codullo, Veronica
A1 Mosca, Marta
A1 Barsotti, Simone
A1 Neri, Rossella
A1 Scirè, Carlo
A1 Govoni, Marcello
A1 Furini, Federica
A1 Lopez-Longo, Francisco Javier
A1 Martinez-Barrio, Julia
A1 Schneider, Udo
A1 Lorenz, Hanns-Martin
A1 Doria, Andrea
A1 Ghirardello, Anna
A1 Ortego-Centeno, Norberto
A1 Confalonieri, Marco
A1 Tomietto, Paola
A1 Pipitone, Nicolò
A1 Rodriguez Cambron, Ana Belen
A1 Blázquez Cañamero, María Ángeles
A1 Voll, Reinhard Edmund
A1 Wendel, Sarah
A1 Scarpato, Salvatore
A1 Maurier, Francois
A1 Limonta, Massimiliano
A1 Colombelli, Paolo
A1 Giannini, Margherita
A1 Geny, Bernard
A1 Arrigoni, Eugenio
A1 Bravi, Elena
A1 Migliorini, Paola
A1 Mathieu, Alessandro
A1 Piga, Matteo
A1 Drott, Ulrich
A1 Delbrueck, Christiane
A1 Bauhammer, Jutta
A1 Cagnotto, Giovanni
A1 Vancheri, Carlo
A1 Sambataro, Gianluca
A1 De Langhe, Ellen
A1 Sainaghi, Pier Paolo
A1 Monti, Cristina
A1 Gigli Berzolari, Francesca
A1 Romano, Mariaeva
A1 Bonella, Francesco
A1 Specker, Christof
A1 Schwarting, Andreas
A1 Villa Blanco, Ignacio
A1 Selmi, Carlo
A1 Ceribelli, Angela
A1 Nuno, Laura
A1 Mera-Varela, Antonio
A1 Perez Gomez, Nair
A1 Fusaro, Enrico
A1 Parisi, Simone
A1 Sinigaglia, Luigi
A1 Del Papa, Nicoletta
A1 Benucci, Maurizio
A1 Cimmino, Marco Amedeo
A1 Riccieri, Valeria
A1 Conti, Fabrizio
A1 Sebastiani, Gian Domenico
A1 Iuliano, Annamaria
A1 Emmi, Giacomo
A1 Cammelli, Daniele
A1 Sebastiani, Marco
A1 Manfredi, Andreina
A1 Bachiller-Corral, Javier
A1 Sifuentes Giraldo, Walter Alberto
A1 Paolazzi, Giuseppe
A1 Saketkoo, Lesley Ann
A1 Giorgi, Roberto
A1 Salaffi, Fausto
A1 Cifrian, Jose
A1 Caporali, Roberto
A1 Locatelli, Francesco
A1 Marchioni, Enrico
A1 Pesci, Alberto
A1 Dei, Giulia
A1 Pozzi, Maria Rosa
A1 Claudia, Lomater
A1 Distler, Jorg
A1 Knitza, Johannes
A1 Schett, George
A1 Iannone, Florenzo
A1 Fornaro, Marco
A1 Franceschini, Franco
A1 Quartuccio, Luca
A1 Gerli, Roberto
A1 Bartoloni, Elena
A1 Bellando Randone, Silvia
A1 Zampogna, Giuseppe
A1 Gonzalez Perez, Montserrat I
A1 Mejia, Mayra
A1 Vicente, Esther
A1 Triantafyllias, Konstantinos
A1 Lopez-Mejias, Raquel
A1 Matucci-Cerinic, Marco
A1 Selva-O'Callaghan, Albert
A1 Castañeda, Santos
A1 Montecucco, Carlomaurizio
A1 Gonzalez-Gay, Miguel Angel
K1 antisynthetase antibodies
K1 antisynthetase syndrome
K1 arthritis
K1 interstitial lung disease
K1 myositis
AB Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
SN 2077-0383
YR 2019
FD 2019-11-18
LK http://hdl.handle.net/10668/14721
UL http://hdl.handle.net/10668/14721
LA en
DS RISalud
RD Apr 10, 2025